Skip to main content
SpringerLink
Log in

Stratégies thérapeutiques des cancers du sein métastatiques : RH+ HER2−. Hormonothérapies, chimiothérapies (monochimiothérapies séquentielles ou polychimiothérapies concomitantes ?), antiangiogéniques

  • Chapter
Cancer du sein en situation métastatique

  • 229 Accesses

Résumé

La prise en charge d’une patiente atteinte d’un cancer du sein métastatique est complexe.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Chia SK, Speers CH, D’yachkova Y et al. (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110: 973–979

    Article  PubMed  Google Scholar 

  2. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P (2005) Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 104: 1742–1750

    Article  PubMed  Google Scholar 

  3. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN (2004) Is breast cancer survival improving? Cancer 100: 44–52

    Article  PubMed  Google Scholar 

  4. Andre F, Slimane K, Bachelot T et al. (2004) Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 22: 3302–3308

    Article  PubMed  Google Scholar 

  5. Largillier R, Ferrero JM, Doyen J et al. (2008) Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol 19: 2012–2019

    Article  PubMed  CAS  Google Scholar 

  6. Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH (2008) Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 26: 4891–4898

    Article  PubMed  Google Scholar 

  7. Delozier T, Switsers O, Ollivier J-M, Levy C, Rivière A, Allouache D (2008) Centre Francois Baclesse, Caen, France. Did survival of patients with distant metastasis from breast cancer improve during the last three decades? A cohort study on 4071 breast cancers. 31st Annual San Antonio Breast Cancer Symposium, Abstract 3129

    Google Scholar 

  8. Dafni U, Grimani I, Xyrafas A, Eleftheraki AG, Fountzilas G (2010) Fifteenyear trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat 119: 621–631

    Article  PubMed  CAS  Google Scholar 

  9. Fountzilas G, Dafni U, Dimopoulos MA et al. (2008) A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: A Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat May 16. [Epub ahead of print]

    Google Scholar 

  10. Seidman AD, Berry D, Cirrincione C et al. (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26: 1642–1649

    Article  PubMed  CAS  Google Scholar 

  11. Albain KS, Nag SM, Calderillo-Ruiz G et al. (2008) Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 26: 3950–3957

    Article  PubMed  Google Scholar 

  12. Robert N, Leyland-Jones B, Asmar L et al. (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24: 2786–2792

    Article  PubMed  CAS  Google Scholar 

  13. Feher O, Vodvarka P, Jassem J et al. (2005) First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol 16: 899–908

    Article  PubMed  CAS  Google Scholar 

  14. Bontenbal M, Creemers GJ, Braun HJ et al. (2005) Dutch Community Setting Trial for the Clinical Trial Group. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 23: 7081–7088

    Article  PubMed  CAS  Google Scholar 

  15. Jones SE, Erban J, Overmoyer B et al. (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23: 5542–5551

    Article  PubMed  CAS  Google Scholar 

  16. Icli F, Akbulut H, Uner A et al. (2005) Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. Br J Cancer 92: 639–644

    Article  PubMed  CAS  Google Scholar 

  17. Marty M, Cognetti F, Maraninchi D et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265–4274

    Article  PubMed  CAS  Google Scholar 

  18. Reyno L, Seymour L, Tu D et al. (2004) National Cancer Institute of Canada Clinical Trials Group Study MA.19. Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. J Clin Oncol 22: 269–276

    Article  PubMed  CAS  Google Scholar 

  19. O’Shaughnessy J, Miles D, Vukelja S et al. (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812–2823

    Article  PubMed  Google Scholar 

  20. Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344: 783–792

    Article  PubMed  CAS  Google Scholar 

  21. Jassem J, Pie_kowski T, P_uza_ska A et al. Central & Eastern Europe and Israel Pacitaxel Breast Cancer Study Group. (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19: 1707–1715

    PubMed  CAS  Google Scholar 

  22. Pacini P, Rinaldini M, Algeri R et al. (2000) FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results. Eur J Cancer 36: 966–975

    Article  PubMed  CAS  Google Scholar 

  23. Nabholtz JM, Senn HJ, Bezwoda WR et al. (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17: 1413–1424

    PubMed  CAS  Google Scholar 

  24. Bishop JF, Dewar J, Toner GC et al. (1999) Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol. 17: 2355–2364

    PubMed  CAS  Google Scholar 

  25. Estaban E, Lacave AJ, Fernández JL et al. (1999) Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer. Breast Cancer Res Treat 58: 141–150

    Article  PubMed  CAS  Google Scholar 

  26. Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP (2006) Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 98: 1285–1291

    Article  PubMed  CAS  Google Scholar 

  27. Cutler SJ, Ardyce JA, Taylor SG 3rd (1969) Classification of patients with disseminated cancer of the breast. Cancer 24: 861–869

    Article  PubMed  CAS  Google Scholar 

  28. Geels P, Eisenhauer E, Bezjak A, Zee B, Day A (2000) Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 18: 2395–2405

    PubMed  CAS  Google Scholar 

  29. Coates A, Gebski V, Bishop JF et al. (1987) Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 317: 1490–1495

    Article  PubMed  CAS  Google Scholar 

  30. Ramirez AJ, Towlson KE, Leaning MS, Richards MA, Rubens RD (1998) Do patients with advanced breast cancer benefit from chemotherapy? Br J Cancer 78: 1488–1494

    Article  PubMed  CAS  Google Scholar 

  31. Modi S, Panageas KS, Duck ET et al. (2002) Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer. J Clin Oncol 20: 3665–3673

    Article  PubMed  CAS  Google Scholar 

  32. Tannock IF, Boyd NF, DeBoer G et al. (1988) A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6: 1377–1387

    PubMed  CAS  Google Scholar 

  33. Fraser SC, Dobbs HJ, Ebbs SR, Fallowfield LJ, Bates T, Baum M (1993) Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life. Br J Cancer 67: 402–406

    Article  PubMed  CAS  Google Scholar 

  34. Bernhard J, Thürlimann B, Schmitz SF et al. (1999) Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter? J Clin Oncol 17:1672–1679

    PubMed  CAS  Google Scholar 

  35. NICE (2002) Guidance on Cancer Services — Improving Outcomes in Breast Cancer. Manual update. http://www.nice.org.uk/nicemedia/pdf/Improving_out-comes_breastcancer_manual.pdf

    Google Scholar 

  36. Crown J, Diéras V, Kaufmann M et al. (2002) Chemotherapy for metastatic breast cancer-report of a European expert panel. Lancet Oncol 3: 719–727

    Article  PubMed  CAS  Google Scholar 

  37. von Minckwitz G; for The Breast Commission of the German Gynaecological Oncology Working Group (AGO) (2006) Evidence-based treatment of metastatic breast cancer — 2006 recommendations by the AGO Breast Commission. Eur J Cancer 42: 2897–2908

    Article  Google Scholar 

  38. Beslija S, Bonneterre J, Burstein HJ et al. Central European Cooperative Oncology Group (CECOG) (2009) Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 20: 1771–1785

    Article  PubMed  CAS  Google Scholar 

  39. Cardoso F, Castiglione M; ESMO Guidelines Working Group (2009) Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20Suppl 4: 15–18

    PubMed  Google Scholar 

  40. NCCN (2008) NCCN Clinical Practice Guidelines in Oncology. Breast Cancer V2. http//www.nccn.org/professionals/physician_gls/PDF/breast.pdf

    Google Scholar 

  41. Wilcken N, Hornbuckle J, Ghersi D (2003) Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev: CD002747. http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002747/frame.html

    Google Scholar 

  42. The Australian and New Zealand Breast Cancer Trials Group (ANZBCTG), Clinical Oncological Society of Australia (1986) A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. J Clin Oncol 4: 186–193

    Google Scholar 

  43. Taylor SG 4th, Gelman RS, Falkson G, Cummings FJ (1986) Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med 104: 455–461

    PubMed  Google Scholar 

  44. Fossati R, Confalonieri C, Torri V et al. (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16: 3439–3460

    PubMed  CAS  Google Scholar 

  45. Piccart-Gebhart MJ, Burzykowski T, Buyse M et al. (2008) Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 26: 1980–1986

    Article  PubMed  CAS  Google Scholar 

  46. Wilcken N, Dear R (2008) Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007. Eur J Cancer 44: 2218–2225

    Article  PubMed  CAS  Google Scholar 

  47. Robain M, Pierga JY, Jouve M et al. (2000) Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer. Eur J Cancer 36: 2301–2312

    Article  PubMed  CAS  Google Scholar 

  48. Alexandre J, Bleuzen P, Bonneterre J et al. (2000) Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 18: 562–573

    PubMed  CAS  Google Scholar 

  49. Gregory WM, Smith P, Richards MA, Twelves CJ, Knight RK, Rubens RD (1993) Chemotherapy of advanced breast cancer: outcome and prognostic factors. Br J Cancer 68: 988–995

    Article  PubMed  CAS  Google Scholar 

  50. Falkson G, Gelman R, Falkson CI, Glick J, Harris J (1991) Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study. J Clin Oncol 9: 2153–2161

    PubMed  CAS  Google Scholar 

  51. Hortobagyi GN, Smith TL, Legha SS et al. (1983) Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1: 776–786

    PubMed  CAS  Google Scholar 

  52. Nabholtz JM, Buzdar A, Pollak M et al. (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18: 3758–3767

    PubMed  CAS  Google Scholar 

  53. Bonneterre J, Thürlimann B, Robertson JF et al. (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18: 3748–3757

    PubMed  CAS  Google Scholar 

  54. Mouridsen H, Gershanovich M, Sun Y et al. (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21: 2101–2109

    Article  PubMed  CAS  Google Scholar 

  55. Paridaens RJ, Dirix LY, Beex LV et al. (2008) Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 26: 4883–4890

    Article  PubMed  CAS  Google Scholar 

  56. Nabholtz JM, Bonneterre J, Buzdar A, Robertson JF, Thürlimann B (2003) Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 39: 1684–1689

    Article  PubMed  CAS  Google Scholar 

  57. Cheung K, Robertson J (1999) The importance of stable disease in breast cancer patients treated with endocrine therapy. Breast Cancer 1: 2–4

    Article  Google Scholar 

  58. Howell A, Mackintosh J, Jones M et al. (1988) The definition of the’ no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 24: 1267–1272

    Google Scholar 

  59. Robertson JF, Williams MR, Todd J, Nicholson RI, Morgan DA, Blamey RW (1989) Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol 25: 469–475

    Article  PubMed  CAS  Google Scholar 

  60. Robertson JF, Willsher PC, Cheung KL, Blamey RW (1997) The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer 33: 1774–1779

    Article  PubMed  CAS  Google Scholar 

  61. Robertson JF, Howell A, Buzdar A, von Euler M, Lee D (1999) Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. Breast Cancer Res Treat 58: 157–162

    Article  PubMed  CAS  Google Scholar 

  62. Mouridsen H, Gershanovich M, Sun Y et al. (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596–2606

    PubMed  CAS  Google Scholar 

  63. Robertson JF, Dixon AR, Nicholson RI, Ellis IO, Elston CW, Blamey RW (1992) Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy. Breast Cancer Res Treat 22: 221–227

    Article  PubMed  CAS  Google Scholar 

  64. Nicholson RI, Bouzubar N, Walker KJ et al. (1991) Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation. Eur J Cancer 27: 908–913

    Article  PubMed  CAS  Google Scholar 

  65. Mouridsen H, Sun Y, Gershanovich M et al. (2004) Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability. Oncologist 9: 489–496

    Article  PubMed  CAS  Google Scholar 

  66. Howell A, Robertson JF, Vergote I (2003) A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. Breast Cancer Res Treat 82: 215–222

    Article  PubMed  CAS  Google Scholar 

  67. Campos SM, Guastalla JP, Subar M, Abreu P, Winer EP, Cameron DA (2009) A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer 9: 39–44

    Article  PubMed  CAS  Google Scholar 

  68. Mauriac L, Romieu G, Bines J (2009) Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial. Breast Cancer Res Treat 117: 69–75

    Article  PubMed  CAS  Google Scholar 

  69. Mauriac L, Pippen JE, Quaresma Albano J, Gertler SZ, Osborne CK (2003) Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer 39: 1228–1233

    Article  PubMed  CAS  Google Scholar 

  70. Mouridsen HT (2007) Letrozole in advanced breast cancer: the PO25 trial. Breast Cancer Res Treat 105Suppl 1:19–29

    Article  PubMed  CAS  Google Scholar 

  71. NICE (2009) http://guidance.nice.org.uk/CG81/Guidance/pdf/English

    Google Scholar 

  72. Guastalla JP, Campone M, Ganem G et al. (2007) Traitement médical du cancer du sein métastatique. Compte rendu du cours supérieur francophone de cancérologie. Saint-Paul-de-Vence, 18–20 janvier. Eds Springer, p 205–237.

    Google Scholar 

  73. Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N (2009) Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev;(2): CD003372

    Google Scholar 

  74. Debled M, Madranges N, Trainaud A et al. (2009) First-line capecitabine monotherapy for slowly progressing metastatic breast cancer: do we need aggressive treatment? Oncology 77: 318–327

    Article  PubMed  CAS  Google Scholar 

  75. Gennari A, Sormani M, Bruzzi P et al. (2008) A meta-analysis of chemotherapy duration in metastatic breast cancer (MBC). J Clin Oncol 26suppl, Abstr 1067

    Google Scholar 

  76. Falkson G, Gelman RS, Pandya KJ et al. (1998) Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 16: 1669–1676

    PubMed  CAS  Google Scholar 

  77. Muss HB, Case LD, Richards F 2nd et al. (1991) Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 325: 1342–1348

    Article  PubMed  CAS  Google Scholar 

  78. Coates A, Gebski V, Signorini D et al. (1992) Prognostic value of quality-oflife scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. J Clin Oncol 10: 1833–1838

    PubMed  CAS  Google Scholar 

  79. Becher R, Kloke O, Hayungs J et al. (1996) Epirubicin and ifosfamide in metastatic breast cancer. Semin Oncol 23(Suppl 7): 28–33

    PubMed  CAS  Google Scholar 

  80. Blum JL, Jones SE, Buzdar AU et al. (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485–493

    PubMed  CAS  Google Scholar 

  81. Kloke O, Klaassen U, Oberhoff C et al. (1999) Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Essen Breast Cancer Study Group. Breast Cancer Res Treat 55: 51–59

    Article  PubMed  CAS  Google Scholar 

  82. Berruti A, Zola P, Buniva T et al. (1997) Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after firstline chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survival. Anticancer Res 17: 2763–2768

    CAS  Google Scholar 

  83. Dufresne A, Pivot X, Tournigand C et al. (2008) Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer. Int J Med Sci. 2008 5: 100–105

    PubMed  CAS  Google Scholar 

  84. Montemurro F, Rondón G, Ueno NT, Munsell M, Gajewski JL, Champlin RE (2002) Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy. Bone Marrow Transplant 29: 861–866

    Article  PubMed  CAS  Google Scholar 

  85. Jones S, Winer E, Vogel C et al. (1995) Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13: 2567–274

    PubMed  CAS  Google Scholar 

  86. Nabholtz JM, Senn HJ, Bezwoda WR et al. (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17: 1413–1424

    PubMed  CAS  Google Scholar 

  87. O’Shaughnessy J, Miles D, Vukelja S et al. (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812–2823

    Article  PubMed  Google Scholar 

  88. Cardoso F, Di LA, Lohrisch C, Bernard C, Ferreira F, Piccart MJ (2002) Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 13: 197–207

    Article  PubMed  CAS  Google Scholar 

  89. Buzdar AU, Smith R, Vogel C et al. (1996) Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer 77: 2503–2513

    Article  PubMed  CAS  Google Scholar 

  90. Buzdar A, Jonat W, Howell A et al. (1996) Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 14: 2000–2011

    PubMed  CAS  Google Scholar 

  91. Thurlimann B, Castiglione M, Hsu-Schmitz SF et al. (1997) Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Eur J Cancer 33: 1017–1024

    Article  PubMed  CAS  Google Scholar 

  92. Buzdar AU, Jonat W, Howell A et al. (1998) Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 83: 1142–1152

    CAS  Google Scholar 

  93. Dombernowsky P, Smith I, Falkson G et al. (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16: 45361

    Google Scholar 

  94. Goss PE, Winer EP, Tannock IF et al. (1999) Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. J Clin Oncol 17: 5263

    Google Scholar 

  95. Kaufmann M, Bajetta E, Dirix LY et al. (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 18: 1399411

    Google Scholar 

  96. Buzdar A, Douma J, Davidson N et al. (2001) A phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 19: 3357–3366

    PubMed  CAS  Google Scholar 

  97. Rose C, Vtoraya O, Pluzanska A et al. (2003) An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39: 2318–2327

    Article  PubMed  CAS  Google Scholar 

  98. Chia S, Gradishar W, Mauriac L et al. (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26: 1664–1670

    Article  PubMed  CAS  Google Scholar 

  99. Thürlimann B, Robertson JF, Nabholtz JM, Buzdar A, Bonneterre J; Arimidex Study Group (2003) Efficacy of tamoxifen following anastrozole (‘Arimidex’) compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 39: 2310–2317

    Article  PubMed  Google Scholar 

  100. Cheung KL, Willsher PC, Pinder SE et al. (1997) Predictors of response to second-line endocrine therapy for breast cancer. Breast Cancer Res Treat 45: 219–224

    Article  PubMed  CAS  Google Scholar 

  101. Miller KD, Chap LI, Holmes FA et al. (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792–799

    Article  PubMed  CAS  Google Scholar 

  102. Miller K, Wang M, Gralow J et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666–2676

    Article  PubMed  CAS  Google Scholar 

  103. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL (2009) Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 27: 4966–4972

    Article  PubMed  CAS  Google Scholar 

  104. Miles DW, Chan A, Romieu G et al. (2009) Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC). 32nd Annual San Antonio Breast Cancer Symposium, Abstract 41

    Google Scholar 

  105. Robert N, Dieras V, Glaspy J et al. (2009) RIBBON-1: a randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of HER-2-negative locally recurrent or metastátic breast cancer. ASCO Annual Meeting Proceedings. J Clin Oncol 27(suppl): abstract 1005

    Google Scholar 

  106. Brufsky A, Bondarenko IN, Smirnov V et al. (2009) RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer. 32nd Annual San Antonio Breast Cancer Symposium, Abstract 42

    Google Scholar 

  107. Gradishar WJ, Kaklamani V, Prasad Sahoo T et al. (2009) A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC). 32nd Annual San Antonio Breast Cancer Symposium, Abstract 44

    Google Scholar 

  108. Baselga J, Roché H, Costa F et al. (2009) SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC). 32nd Annual San Antonio Breast Cancer Symposium, Abstract 45

    Google Scholar 

  109. Barrios C, Liu M-C, Lee SC et al. (2009) Phase III Randomized Trial of Sunitinib (SU) vs. Capecitabine (C) in Patients (Pts) with Previously Treated HER2-Negative Advanced Breast Cancer (ABC). 32nd Annual San Antonio Breast Cancer Symposium, Abstract 46

    Google Scholar 

  110. Matsuyama R, Reddy S, Smith TJ (2006) Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 24: 3490–3496

    Article  PubMed  Google Scholar 

  111. Earle CC (2006) Do unto others... J Clin Oncol 24: 3331–3332

    Article  PubMed  Google Scholar 

  112. Banerji U, Kuciejewska A, Ashley S et al. (2007) Factors determining outcome after third line chemotherapy for metastatic breast cancer. Breast 16: 359–366

    Article  PubMed  Google Scholar 

  113. Dufresne A, Pivot X, Tournigand C et al. (2008) Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res Treat 107: 275–279

    Article  PubMed  CAS  Google Scholar 

  114. Vauléon E, Mesbah H, Laguerre B et al. (2009) Usefulness of chemotherapy beyond the second line for metastatic breast cancer: a therapeutic challenge. Cancer Chemother Pharmacol Sep 27 [Epub ahead of print]

    Google Scholar 

  115. McLachlan SA, Pintilie M, Tannock IF (1999) Third line chemotherapy in patients with metastatic breast cancer: an evaluation of quality of life and cost. Breast Cancer Res Treat 54: 213–223

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut Bergonié, 229 Cours de l’Argonne, 33076, Bordeaux Cedex

    M. Debled & L. Mauriac

Authors
  1. M. Debled
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Mauriac
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag France

About this chapter

Cite this chapter

Debled, M., Mauriac, L. (2010). Stratégies thérapeutiques des cancers du sein métastatiques : RH+ HER2−. Hormonothérapies, chimiothérapies (monochimiothérapies séquentielles ou polychimiothérapies concomitantes ?), antiangiogéniques. In: Cancer du sein en situation métastatique. Springer, Paris. https://doi.org/10.1007/978-2-8178-0076-9_20

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0076-9_20

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0075-2

  • Online ISBN: 978-2-8178-0076-9

Publish with us

Policies and ethics

Search

Navigation